机器学习方法有助于在患有SLCO1B1变体的缺血性中风患者中选择ezetimibe或他类药物
Chaohua Cui1, Tonghua Long2, Haoye Guan2
1Life Science and Clinical Medicine Research Center, Affiliated Hospital of Youjiang Medical University for Nationalities, Youjiang District, Baise, Guangxi, China. cchaiwp@163.com.
European journal of medical research
|December 23, 2025
概括
在患有SLCO1B1变异的急性缺血性中风患者中使用ezetimibe可以减少中风复发和他类药物的副作用,同时改善LDL-C水平. 这表明,与他类药物相比,ezetimibe在这个患者群体中提供了更好的预后.
科学领域:
- 心血管医学 心血管医学
- 药物基因组学 药物基因组学
- 神经学 神经学
背景情况:
- 在急性缺血性中风患者中,他类药物增加了SLCO1B1变体的副作用风险.
- 埃泽提米布可以达到推的低密度脂蛋白胆固醇 (LDL-C) 水平,副作用较少.
- 需要在这个人群中直接比较ezetimibe和他类药物.
研究的目的:
- 在患有SLCO1B1变异的急性缺血性中风患者中,比较以泽提米布与他类药物的疗效和安全性.
- 为了评估中风复发,LDL-C水平和副作用.
- 评估功能结果并确定预后因素.
主要方法:
- 对患有SLCO1B1变异的急性缺血性中风患者的回顾性分析.
- 主要结局:中风在1年内复发,并在30天内达到建议的LDL-C水平.
- 二次结果:功能结果和他类药物的副作用.
主要成果:
- 埃泽胺组的中风复发率较低 (6.3%对17.9%),他类药物的副作用较少 (3.2%对13.7%).
- 埃泽胺组中更高的比例达到推的LDL-C水平 (81.0%vs48.4%).
- 使用ezetimibe与减少中风复发,更好的LDL-C控制和更少的副作用有关,但没有改善功能结果.
结论:
- 在患有SLCO1B1变异的急性缺血性中风患者中,埃泽蒂米布的安全性和有效性比他类药物更好.
- 埃泽胺使用与中风复发和副作用的风险降低,以及改善LDL-C管理有关.
- 埃泽提米布可能提供更好的预后,特别是在男性,年轻的患者,具有特定的风险因素.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
01:26Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291
01:26Pharmacokinetic Models: Comparison and Selection Criterion
304
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
304
01:27Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
430
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
430